Success Metrics

Clinical Success Rate
87.4%

Based on 26,597 completed trials

Completion Rate
87%(26597/30418)
Active Trials
4,822(12%)
Results Posted
48%(12652 trials)
Terminated
3,821(9%)

Phase Distribution

Ph phase_1
8,095
20%
Ph early_phase_1
569
1%
Ph phase_3
8,862
21%
Ph not_applicable
6,816
16%
Ph phase_2
12,800
31%
Ph phase_4
4,142
10%

Phase Distribution

8664

Early Stage

12800

Mid Stage

13004

Late Stage

Phase Distribution41284 total trials
Early Phase 1First-in-human
569(1.4%)
Phase 1Safety & dosage
8,095(19.6%)
Phase 2Efficacy & side effects
12,800(31.0%)
Phase 3Large-scale testing
8,862(21.5%)
Phase 4Post-market surveillance
4,142(10.0%)
N/ANon-phased studies
6,816(16.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.7%

26597 of 31791 finished

Non-Completion Rate

16.3%

5194 ended early

Currently Active

4822

trials recruiting

Total Trials

41,384

all time

Status Distribution
Active(6283)
Completed(26597)
Terminated(5194)
Other(3310)

Detailed Status

Completed26597
Terminated3821
Recruiting3402
unknown3196
Active, not recruiting1420
Withdrawn1373

Development Timeline

Analytics

Development Status

Total Trials
41384
Active
4822
Success Rate
87.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 1569 (1.4%)
Phase 18095 (19.6%)
Phase 212800 (31.0%)
Phase 38862 (21.5%)
Phase 44142 (10.0%)
N/A6816 (16.5%)

Trials by Status

active_not_recruiting14203%
not_yet_recruiting13393%
recruiting34028%
unknown31968%
terminated38219%
withdrawn13733%
completed2659764%
suspended1140%
enrolling_by_invitation1220%

Recent Activity

Clinical Trials (41,384)

Showing 20 of 41,384 trialsScroll for more
NCT07058077Phase 2

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

Recruiting
NCT05327114Phase 2

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting
NCT07284459Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Recruiting
NCT05713799Phase 2

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

Not Yet Recruiting
NCT07111065Phase 2

FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)

Recruiting
NCT05531565Phase 2

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Active Not Recruiting
NCT06540833Phase 2

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Recruiting
NCT06990269Phase 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Recruiting
NCT01681264Phase 4

Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance

Terminated
NCT07513376Phase 3

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Recruiting
NCT06077760Phase 3

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Recruiting
NCT05138133Phase 3

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Active Not Recruiting
NCT06274749Not Applicable

Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial

Recruiting
NCT06628622Phase 1

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine

Terminated
NCT06745921Phase 1

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

Active Not Recruiting
NCT05889182Phase 3

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Recruiting
NCT04123795Phase 3

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

Completed
NCT06690398Phase 3

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients

Recruiting
NCT06948097Phase 1

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

Not Yet Recruiting
NCT06963827Phase 3

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

Recruiting

Drug Details

Intervention Type
OTHER
Total Trials
41,384